Etoposide, doxorubicin, cyclophosphamide and high-dose betamethasone (EACB) as outpatient salvage therapy for refractory multiple myeloma-Reference-Cited by-同舟云学术

Etoposide, doxorubicin, cyclophosphamide and high-dose betamethasone (EACB) as outpatient salvage therapy for refractory multiple myeloma

Published:2009-04-24 Issue:1 Volume:51 Page:45-49
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Ohrling M.,Björkholm M.,Österborg A.,Juliusson G.,Björeman M.,Brenning G.,Carlson K.,Celsing F.,Gahrton G.,Grimfors G.,Gruber A.,Gyllenhammar H.,Hast R.,Johansson B.,Järnmark M.,Kimby E.,Lerner R.,Linder O.,Merk K.,Paul C.,Simonsson B.,Smedmyr B.,Svedmyr E.,Stalfelt A.-M.,Udén A.-M.,Ösby E.,Mellstedt H.

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.1993.tb00603.x/fullpdf

Reference27 articles.

1. Management of refractory myeloma: A review;Buzaid;J Clin Oncol,1988

2. Effective treatment of advanced multiple myeloma refractory to alkylating agents;Barlogie;N Engl J Med,1984

3. The efficacy and toxicity of VAD in the treatment of myeloma and related disorders;Sheehan;Scand J Haematol,1986

4. Combination chemotherapy with vincristine, doxorubicin, dexamethasone for refractory or relapsing multiple myeloma;Monconduit;Br J Haematol,1986

5. Chemotherapy for resistant and relapsing multiple myeloma;Alexanian;Cancer Bull,1990

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fludarabine and plasma cell leukemia;European Journal of Haematology;2009-04-24

2. Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003;Journal of Clinical Oncology;2007-05-20

3. Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone);Hematological Oncology;2007

4. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: An international oncology study group (IOSG) phase II protocol;American Journal of Hematology;2000-03

5. Multiples Myelom (Plasmozytom);Therapiekonzepte Onkologie;1998